Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1957 2
1958 8
1961 2
1962 1
1964 2
1966 2
1968 7
1969 2
1974 1
1976 3
1977 2
1978 1
1979 2
1980 1
1981 1
1982 2
1983 1
1984 4
1985 2
1986 10
1987 5
1988 6
1989 6
1990 7
1991 7
1992 4
1993 3
1994 2
1995 3
1996 5
1997 3
1998 2
1999 6
2000 1
2001 2
2002 4
2003 6
2004 5
2005 10
2006 11
2007 10
2008 9
2009 3
2010 6
2011 13
2012 15
2013 4
2014 5
2015 9
2016 10
2017 5
2018 14
2019 17
2020 19
2021 7
2022 14
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

298 results

Results by year

Filters applied: . Clear all
Page 1
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators. Schrier RW, et al. Among authors: orlandi c. N Engl J Med. 2006 Nov 16;355(20):2099-112. doi: 10.1056/NEJMoa065181. Epub 2006 Nov 14. N Engl J Med. 2006. PMID: 17105757 Free article. Clinical Trial.
Orphan receptor GPR158 controls stress-induced depression.
Sutton LP, Orlandi C, Song C, Oh WC, Muntean BS, Xie K, Filippini A, Xie X, Satterfield R, Yaeger JDW, Renner KJ, Young SM Jr, Xu B, Kwon H, Martemyanov KA. Sutton LP, et al. Among authors: orlandi c. Elife. 2018 Feb 8;7:e33273. doi: 10.7554/eLife.33273. Elife. 2018. PMID: 29419376 Free PMC article.
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Konstam MA, et al. Among authors: orlandi c. JAMA. 2007 Mar 28;297(12):1319-31. doi: 10.1001/jama.297.12.1319. Epub 2007 Mar 25. JAMA. 2007. PMID: 17384437 Clinical Trial.
Genetic behavioral screen identifies an orphan anti-opioid system.
Wang D, Stoveken HM, Zucca S, Dao M, Orlandi C, Song C, Masuho I, Johnston C, Opperman KJ, Giles AC, Gill MS, Lundquist EA, Grill B, Martemyanov KA. Wang D, et al. Among authors: orlandi c. Science. 2019 Sep 20;365(6459):1267-1273. doi: 10.1126/science.aau2078. Epub 2019 Aug 15. Science. 2019. PMID: 31416932 Free PMC article.
Gα Protein Signaling Bias at Serotonin 1A Receptor.
Alabdali R, Franchini L, Orlandi C. Alabdali R, et al. Among authors: orlandi c. Mol Pharmacol. 2023 Nov;104(5):230-238. doi: 10.1124/molpharm.123.000722. Epub 2023 Aug 11. Mol Pharmacol. 2023. PMID: 37567783 Free PMC article.
298 results